{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:01:25Z","timestamp":1791378085836,"version":"4.3.2"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2011\/22376-7"],"award-info":[{"award-number":["2011\/22376-7"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2017\/21801-2"],"award-info":[{"award-number":["2017\/21801-2"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s00262-021-03111-2","type":"journal-article","created":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:03:57Z","timestamp":1642464237000},"page":"1909-1921","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Novel inhibitor of hematopoietic cell kinase as a potential therapeutic agent for acute myeloid leukemia"],"prefix":"10.1007","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8285-918X","authenticated-orcid":false,"given":"Fernanda Marconi","family":"Roversi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maura Lima Pereira","family":"Bueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliete Aparecida Francisco","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme Rossi","family":"Assis-Mendon\u00e7a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiane Okuda","family":"Torello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo Nato","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando Viera","family":"Pericole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla Priscila","family":"Ferro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana Santos Silva","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo Magalh\u00e3es","family":"Rego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Teresinha Olalla","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,18]]},"reference":[{"issue":"1","key":"3111_CR1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12943-016-0571-x","volume":"16","author":"KS Siveen","year":"2017","unstructured":"Siveen KS, Uddin S, Mohammad RM (2017) Targeting acute myeloid leukemia stem cell signaling by natural products. Mol Cancer 16(1):13. https:\/\/doi.org\/10.1186\/s12943-016-0571-x","journal-title":"Mol Cancer"},{"issue":"9936","key":"3111_CR2","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1016\/S0140-6736(13)61901-7","volume":"383","author":"L Ades","year":"2014","unstructured":"Ades L, Itzykson R, Fenaux P (2014) Myelodysplastic syndromes. Lancet 383(9936):2239\u20132252. https:\/\/doi.org\/10.1016\/S0140-6736(13)61901-7","journal-title":"Lancet"},{"issue":"4","key":"3111_CR3","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/cncr.31729","volume":"125","author":"AM Brunner","year":"2019","unstructured":"Brunner AM, Neuberg DS, Wander SA, Sadrzadeh H, Ballen KK, Amrein PC, Attar E, Hobbs GS, Chen YB, Perry A, Connolly C, Joseph C, Burke M, Ramos A, Galinsky I, Yen K, Yang H, Straley K, Agresta S, Adamia S, Borger DR, Iafrate A, Graubert TA, Stone RM, Fathi AT (2019) Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia. Cancer 125(4):541\u2013549. https:\/\/doi.org\/10.1002\/cncr.31729","journal-title":"Cancer"},{"issue":"1","key":"3111_CR4","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1182\/blood-2015-08-604520","volume":"127","author":"H Dombret","year":"2016","unstructured":"Dombret H, Gardin C (2016) An update of current treatments for adult acute myeloid leukemia. Blood 127(1):53\u201361. https:\/\/doi.org\/10.1182\/blood-2015-08-604520","journal-title":"Blood"},{"issue":"10","key":"3111_CR5","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1038\/s41375-019-0449-1","volume":"33","author":"A El-Jawahri","year":"2019","unstructured":"El-Jawahri A, Abel GA, Traeger L, Waldman L, Markovitz N, VanDusen H, Fathi A, Steensma DP, LeBlanc TW, Horick NK, DeAngelo DJ, Wadleigh M, Hobbs G, Foster J, Brunner AM, Amrein P, Stone RM, Temel JS, Greer JA (2019) Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy. Leukemia 33(10):2393\u20132402. https:\/\/doi.org\/10.1038\/s41375-019-0449-1","journal-title":"Leukemia"},{"key":"3111_CR6","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1186\/s12885-015-1857-x","volume":"15","author":"M Mohammadi","year":"2015","unstructured":"Mohammadi M, Cao Y, Glimelius I, Bottai M, Eloranta S, Smedby KE (2015) The impact of comorbid disease history on all-cause and cancer-specific mortality in myeloid leukemia and myeloma \u2013 a Swedish population-based study. BMC Cancer 15:850. https:\/\/doi.org\/10.1186\/s12885-015-1857-x","journal-title":"BMC Cancer"},{"issue":"6","key":"3111_CR7","first-page":"1972","volume":"5","author":"F Dubois","year":"2015","unstructured":"Dubois F, Leroy C, Simon V, Benistant C, Roche S (2015) YES oncogenic activity is specified by its SH4 domain and regulates RAS\/MAPK signaling in colon carcinoma cells. Am J Cancer Res 5(6):1972\u20131987","journal-title":"Am J Cancer Res"},{"key":"3111_CR8","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3389\/fgene.2014.00181","volume":"5","author":"I Amata","year":"2014","unstructured":"Amata I, Maffei M, Pons M (2014) Phosphorylation of unique domains of Src family kinases. Front Genet 5:181. https:\/\/doi.org\/10.3389\/fgene.2014.00181","journal-title":"Front Genet"},{"issue":"8","key":"3111_CR9","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1593\/neo.10328","volume":"12","author":"A Aleshin","year":"2010","unstructured":"Aleshin A, Finn RS (2010) SRC: a century of science brought to the clinic. Neoplasia 12(8):599\u2013607. https:\/\/doi.org\/10.1593\/neo.10328","journal-title":"Neoplasia"},{"issue":"4","key":"3111_CR10","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1182\/blood-2007-04-082099","volume":"111","author":"C Dos Santos","year":"2008","unstructured":"Dos Santos C, Demur C, Bardet V, Prade-Houdellier N, Payrastre B, Recher C (2008) A critical role for Lyn in acute myeloid leukemia. Blood 111(4):2269\u20132279. https:\/\/doi.org\/10.1182\/blood-2007-04-082099","journal-title":"Blood"},{"issue":"11","key":"3111_CR11","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1182\/blood-2012-11-466425","volume":"122","author":"C Dos Santos","year":"2013","unstructured":"Dos Santos C, McDonald T, Ho YW, Liu H, Lin A, Forman SJ, Kuo YH, Bhatia R (2013) The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents. Blood 122(11):1900\u20131913. https:\/\/doi.org\/10.1182\/blood-2012-11-466425","journal-title":"Blood"},{"key":"3111_CR12","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aat5916","author":"K Shen","year":"2018","unstructured":"Shen K, Moroco JA, Patel RK, Shi H, Engen JR, Dorman HR, Smithgall TE (2018) The src family kinase fgr is a transforming oncoprotein that functions independently of SH3-SH2 domain regulation. Sci Signal. https:\/\/doi.org\/10.1126\/scisignal.aat5916","journal-title":"Sci Signal"},{"key":"3111_CR13","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1755-8794-3-30","volume":"3","author":"MO Baratti","year":"2010","unstructured":"Baratti MO, Moreira YB, Traina F, Costa FF, Verjovski-Almeida S, Olalla-Saad ST (2010) Identification of protein-coding and non-coding RNA expression profiles in CD34+ and in stromal cells in refractory anemia with ringed sideroblasts. BMC Med Genomics 3:30. https:\/\/doi.org\/10.1186\/1755-8794-3-30","journal-title":"BMC Med Genomics"},{"key":"3111_CR14","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.bbadis.2016.11.013","volume":"2","author":"FM Roversi","year":"1863","unstructured":"Roversi FM, Pericole FV, Machado-Neto JA, Duarte ADSS, Longhini AL, Corrocher FA, Palodetto B, Ferro KP, Rosa RG, Baratti MO, Verjovski-Almeida S, Traina F, Molinari A, Botta M (1863) Saad SOT (2017) Hematopoietic cell kinase (HCK) is a potential therapeutic target for dysplastic and leukemic cells due to integration of erythropoietin\/PI3K pathway and regulation of erythropoiesis: HCK in erythropoietin\/PI3K pathway. Biochim et Biophys Acta (BBA)- Mol Basis Dis 2:450\u2013461. https:\/\/doi.org\/10.1016\/j.bbadis.2016.11.013","journal-title":"Biochim et Biophys Acta (BBA)- Mol Basis Dis"},{"key":"3111_CR15","doi-asserted-by":"publisher","first-page":"6543","DOI":"10.2147\/CMAR.S189287","volume":"11","author":"Z Chen","year":"2019","unstructured":"Chen Z, Shen S, Shi W, Jiang G, Wang X, Jian H, Zhou Z, Ding Z, Lu S (2019) Intercalated combination of chemotherapy and erlotinib for stage IIIA non-small-cell lung cancer: a multicenter, open-label, single-arm, phase II study. Cancer Manag Res 11:6543\u20136552. https:\/\/doi.org\/10.2147\/CMAR.S189287","journal-title":"Cancer Manag Res"},{"issue":"18","key":"3111_CR16","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.4161\/cc.10.18.16599","volume":"10","author":"S Boehrer","year":"2011","unstructured":"Boehrer S, Galluzzi L, Lainey E, Bouteloup C, Tailler M, Harper F, Pierron G, Ad\u00e8s L, Th\u00e9pot S, S\u00e9bert M, Gardin C, de Botton S, Fenaux P, Kroemer G (2011) Erlotinib antagonizes constitutive activation of SRC family kinases and mTOR in acute myeloid leukemia. Cell Cycle 10(18):3168\u20133175. https:\/\/doi.org\/10.4161\/cc.10.18.16599","journal-title":"Cell Cycle"},{"issue":"3","key":"3111_CR17","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s11060-014-1667-z","volume":"121","author":"JW Taylor","year":"2015","unstructured":"Taylor JW, Dietrich J, Gerstner ER, Norden AD, Rinne ML, Cahill DP, Stemmer-Rachamimov A, Wen PY, Betensky RA, Giorgio DH, Snodgrass K, Randall AE, Batchelor TT, Chi AS (2015) Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma. J Neurooncol 121(3):557\u201363. https:\/\/doi.org\/10.1007\/s11060-014-1667-z","journal-title":"J Neurooncol"},{"issue":"1","key":"3111_CR18","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.18632\/oncotarget.13643","volume":"8","author":"S Bieerkehazhi","year":"2017","unstructured":"Bieerkehazhi S, Chen Z, Zhao Y, Yu Y, Zhang H, Vasudevan SA, Woodfield SE, Tao L, Yi JS, Muscal JA, Pang JC, Guan S, Zhang H, Nuchtern JG, Li H, Li H, Yang J (2017) Novel Src\/Abl tyrosine kinase inhibitor bosutinib suppresses neuroblastoma growth via inhibiting Src\/Abl signaling. Oncotarget 8(1):1469\u20131480. https:\/\/doi.org\/10.18632\/oncotarget.13643","journal-title":"Oncotarget"},{"issue":"12","key":"3111_CR19","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1080\/10428194.2018.1452213","volume":"59","author":"RJ MacDonald","year":"2018","unstructured":"MacDonald RJ, Bunaciu RP, Ip V, Dai D, Tran D, Varner JD, Yen A (2018) Src family kinase inhibitor bosutinib enhances retinoic acid-induced differentiation of HL-60 leukemia cells. Leuk Lymphoma 59(12):2941\u20132951. https:\/\/doi.org\/10.1080\/10428194.2018.1452213","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"3111_CR20","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1021\/acschembio.8b00154","volume":"13","author":"MC Weir","year":"2018","unstructured":"Weir MC, Shu ST, Patel RK, Hellwig S, Chen L, Tan L, Gray NS, Smithgall TE (2018) Selective inhibition of the myeloid src-family kinase fgr potently suppresses AML cell growth in vitro and in vivo. ACS Chem Biol 13(6):1551\u20131559. https:\/\/doi.org\/10.1021\/acschembio.8b00154","journal-title":"ACS Chem Biol"},{"issue":"8","key":"3111_CR21","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/cmdc.201300204","volume":"8","author":"C Tintori","year":"2013","unstructured":"Tintori C, Laurenzana I, La Rocca F, Falchi F, Carraro F, Ruiz A, Est\u00e9 JA, Kissova M, Crespan E, Maga G, Biava M, Brullo C, Schenone S, Botta M (2013) Identification of Hck inhibitors as hits for the development of antileukemia and anti-HIV agents. ChemMedChem 8(8):1353\u20131360. https:\/\/doi.org\/10.1002\/cmdc.201300204","journal-title":"ChemMedChem"},{"issue":"2","key":"3111_CR22","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.exphem.2003.11.003","volume":"32","author":"V Ugo","year":"2004","unstructured":"Ugo V, Marzac C, Teyssandier I, Larbret F, L\u00e9cluse Y, Debili N, Vainchenker W, Casadevall N (2004) Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera. Exp Hematol 32(2):179\u2013187. https:\/\/doi.org\/10.1016\/j.exphem.2003.11.003","journal-title":"Exp Hematol"},{"issue":"10","key":"3111_CR23","doi-asserted-by":"publisher","first-page":"5302","DOI":"10.1073\/pnas.94.10.5302","volume":"94","author":"LZ He","year":"1997","unstructured":"He LZ, Tribioli C, Rivi R, Peruzzi D, Pelicci PG, Soares V, Cattoretti G, Pandolfi PP (1997) Acute leukemia with promyelocytic features in PML\/RARalpha transgenic mice. Proc Natl Acad Sci U S A 94(10):5302\u20135307. https:\/\/doi.org\/10.1073\/pnas.94.10.5302","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"13","key":"3111_CR24","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1038\/sj.onc.1209216","volume":"25","author":"EM Rego","year":"2006","unstructured":"Rego EM, Ruggero D, Tribioli C (2006) Leukemia with distinct phenotypes in transgenic mice expressing PML\/RAR alpha. PLZF\/RAR alpha or NPM\/RAR alpha Oncogene 25(13):1974\u20131979. https:\/\/doi.org\/10.1038\/sj.onc.1209216","journal-title":"PLZF\/RAR alpha or NPM\/RAR alpha Oncogene"},{"issue":"3","key":"3111_CR25","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/leu.2011.216","volume":"26","author":"GA dos Santos","year":"2012","unstructured":"dos Santos GA, e Abreu Lima RS, Pestana CR, Lima AS, Scheucher PS, Thom\u00e9 CH, Gimenes-Teixeira HL, Santana-Lemos BA, Lucena-Araujo AR, Rodrigues FP, Nasr R, Uyemura SA, Falc\u00e3o RP, de Th\u00e9 H, Pandolfi PP, Curti C, Rego EM (2012) (+)\u03b1-Tocopheryl succinate inhibits the mitochondrial respiratory chain complex I and is as effective as arsenic trioxide or ATRA against acute promyelocytic leukemia in vivo. Leukemia. 26(3):451\u201360. https:\/\/doi.org\/10.1038\/leu.2011.216","journal-title":"Leukemia."},{"issue":"1","key":"3111_CR26","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1182\/blood-2011-04-347187","volume":"120","author":"RH J\u00e1como","year":"2012","unstructured":"J\u00e1como RH, Santana-Lemos BA, Lima AS et al (2012) Methionine induced hyper homocysteinemia reverts fibrinolytic pathway activation in a murine model of acute promyelocytic leukemia. Blood 120(1):207\u2013213. https:\/\/doi.org\/10.1182\/blood-2011-04-347187","journal-title":"Blood"},{"issue":"11","key":"3111_CR27","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1038\/bjc.2013.510","volume":"109","author":"AK Ferreira","year":"2013","unstructured":"Ferreira AK, Santana-Lemos BA, Rego EM, Filho OM, Chierice GO, Maria DA (2013) Synthetic phosphoethanolamine has in vitro and in vivo anti-leukemia effects. Br J Cancer 109(11):2819\u20132828. https:\/\/doi.org\/10.1038\/bjc.2013.510","journal-title":"Br J Cancer"},{"key":"3111_CR28","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.canlet.2017.11.006","volume":"414","author":"CO Torello","year":"2018","unstructured":"Torello CO, Shiraishi RN, Della Via FI, Castro TCL, Longhini AL, Santos I, Bombeiro AL, Silva CLA, Queiroz MLS, Rego EM, Saad STO (2018) Reactive oxygen species production triggers green tea-induced anti-leukaemic effects on acute promyelocytic leukaemia model. Cancer Lett 414:116\u2013126. https:\/\/doi.org\/10.1016\/j.canlet.2017.11.006","journal-title":"Cancer Lett"},{"issue":"10","key":"3111_CR29","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.3390\/cancers11101618","volume":"11","author":"C Braicu","year":"2019","unstructured":"Braicu C, Buse M, Busuioc C, Drula R, Gulei D, Raduly L, Rusu A, Irimie A, Atanasov AG, Slaby O, Ionescu C, Berindan-Neagoe I (2019) A comprehensive review on MAPK: a promising therapeutic target in cancer. Cancers (Basel) 11(10):1618. https:\/\/doi.org\/10.3390\/cancers11101618","journal-title":"Cancers (Basel)"},{"issue":"4","key":"3111_CR30","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1039\/c8bm01503a","volume":"7","author":"JER Bianco","year":"2019","unstructured":"Bianco JER, Rosa RG, Congrains-Castillo A, Joazeiro PP, Waldman SD, Weber JF, Saad STO (2019) Characterization of a novel decellularized bone marrow scaffold as an inductive environment for hematopoietic stem cells. Biomat Sci 7(4):1516\u20131528. https:\/\/doi.org\/10.1039\/c8bm01503a","journal-title":"Biomat Sci"},{"issue":"8","key":"3111_CR31","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1158\/2159-8290.CD-18-1474","volume":"9","author":"ER Adelman","year":"2019","unstructured":"Adelman ER, Huang HT, Roisman A, Olsson A, Colaprico A, Qin T, Lindsley RC, Bejar R, Salomonis N, Grimes HL, Figueroa ME (2019) Aging human hematopoietic stem cells manifest profound epigenetic reprogramming of enhancers that may predispose to leukemia. Cancer Discov 9(8):1080\u20131101. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-1474","journal-title":"Cancer Discov"},{"key":"3111_CR32","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/nrc3343","volume":"12","author":"AH Shih","year":"2012","unstructured":"Shih AH, Abdel-Wahab O, Patel JP, Levine RL (2012) The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer 12:599\u2013612. https:\/\/doi.org\/10.1038\/nrc3343","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"3111_CR33","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.cger.2015.08.010","volume":"32","author":"HD Klepin","year":"2016","unstructured":"Klepin HD (2016) Myelodysplastic syndromes and acute myeloid leukemia in the elderly. Clin Geriatr Med 32(1):155\u2013173. https:\/\/doi.org\/10.1016\/j.cger.2015.08.010","journal-title":"Clin Geriatr Med"},{"issue":"17","key":"3111_CR34","doi-asserted-by":"publisher","first-page":"3890","DOI":"10.1182\/blood-2011-12-379008","volume":"119","author":"G Juliusson","year":"2012","unstructured":"Juliusson G, Lazarevic V, H\u00f6rstedt AS, Hagberg O, H\u00f6glund M (2012) Acute leukemia registry group. Acute myeloid leukemia in the real world: why population-based registries are needed. Blood 119(17):3890\u20133899. https:\/\/doi.org\/10.1182\/blood-2011-12-379008","journal-title":"Blood"},{"key":"3111_CR35","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/asheducation-2012.1.49","volume":"1","author":"GJ Mufti","year":"2012","unstructured":"Mufti GJ, Potter V (2012) Myelodysplastic syndromes: who and when in the course of disease to transplant. Hematology Am Soc Hematol Educ Program 1:49\u201355. https:\/\/doi.org\/10.1182\/asheducation-2012.1.49","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"23","key":"3111_CR36","doi-asserted-by":"publisher","first-page":"38022","DOI":"10.18632\/oncotarget.16723","volume":"8","author":"R Bayat Mokhtari","year":"2017","unstructured":"Bayat Mokhtari R, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, Yeger H (2017) Combination therapy in combating cancer. Oncotarget 8(23):38022\u201338043. https:\/\/doi.org\/10.18632\/oncotarget.16723","journal-title":"Oncotarget"},{"issue":"8","key":"3111_CR37","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s10147-019-01467-1","volume":"24","author":"K Miyamoto","year":"2019","unstructured":"Miyamoto K, Minami Y (2019) Precision medicine and novel molecular target therapies in acute myeloid leukemia: the background of hematologic malignancies (HM)-SCREEN-Japan 01. Int J Clin Oncol. 24(8):893\u2013898. https:\/\/doi.org\/10.1007\/s10147-019-01467-1","journal-title":"Int J Clin Oncol."},{"key":"3111_CR38","doi-asserted-by":"publisher","first-page":"15752","DOI":"10.18632\/oncotarget.4199","volume":"6","author":"AR Poh","year":"2015","unstructured":"Poh AR, O\u2019Donoghue RJ, Ernst M (2015) Hematopoietic cell kinase (HCK) as a therapeutic target in immune and cancer cells. Oncotarget 6:15752\u201315771. https:\/\/doi.org\/10.18632\/oncotarget.4199","journal-title":"Oncotarget"},{"issue":"3","key":"3111_CR39","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41580-018-0089-8","volume":"20","author":"R Singh","year":"2019","unstructured":"Singh R, Letai A, Sarosiek K (2019) Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nat Rev Mol Cell Biol 20(3):175\u2013193. https:\/\/doi.org\/10.1038\/s41580-018-0089-8","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"3111_CR40","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrm2308","volume":"9","author":"RJ Youle","year":"2008","unstructured":"Youle RJ, Strasser A (2008) The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9(1):47\u201359. https:\/\/doi.org\/10.1038\/nrm2308","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"13","key":"3111_CR41","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1158\/1078-0432.CCR-19-1900","volume":"26","author":"S Jin","year":"2020","unstructured":"Jin S, Cojocari D, Purkal JJ, Popovic R, Talaty NN, Xiao Y, Solomon LR, Boghaert ER, Leverson JD, Phillips DC (2020) 5-azacytidine induces NOXA to prime AML cells for venetoclax-mediated apoptosis. Clin Cancer Res 26(13):3371\u20133383. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1900","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3111_CR42","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1182\/blood-2015-07-604512","volume":"127","author":"BJ Wouters","year":"2016","unstructured":"Wouters BJ, Delwel R (2016) Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia. Blood 127(1):42\u201352. https:\/\/doi.org\/10.1182\/blood-2015-07-604512","journal-title":"Blood"},{"issue":"26","key":"3111_CR43","doi-asserted-by":"publisher","first-page":"39784","DOI":"10.18632\/oncotarget.9289","volume":"7","author":"G Pillinger","year":"2016","unstructured":"Pillinger G, Loughran NV, Piddock RE, Shafat MS, Zaitseva L, Abdul-Aziz A, Lawes MJ, Bowles KM, Rushworth SA (2016) Targeting PI3Kdelta and PI3Kgamma signalling disrupts human AML survival and bone marrow stromal cell mediated protection. Oncotarget 7(26):39784\u201339795. https:\/\/doi.org\/10.18632\/oncotarget.9289","journal-title":"Oncotarget"},{"issue":"3","key":"3111_CR44","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/s41419-021-03504-2","volume":"12","author":"C Zhou","year":"2021","unstructured":"Zhou C, Du J, Zhao L, Liu W, Zhao T, Liang H, Fang P, Zhang K, Zeng H (2021) GLI1 reduces drug sensitivity by regulating cell cycle through PI3K\/AKT\/GSK3\/CDK pathway in acute myeloid leukemia. Cell Death Dis 12(3):231. https:\/\/doi.org\/10.1038\/s41419-021-03504-2","journal-title":"Cell Death Dis"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-021-03111-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-021-03111-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-021-03111-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T16:25:06Z","timestamp":1658161506000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-021-03111-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,18]]},"references-count":44,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["3111"],"URL":"https:\/\/doi.org\/10.1007\/s00262-021-03111-2","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,18]]},"assertion":[{"value":"13 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}